Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddys gets...

    Dr Reddys gets inspection closure report for Duvvada facility from USFDA

    Farhat NasimWritten by Farhat Nasim Published On 2019-02-19T12:30:05+05:30  |  Updated On 19 Feb 2019 12:30 PM IST
    Dr Reddys gets inspection closure report for Duvvada facility from USFDA

    One of the top Indian generic drug companies with major exposure to U.S market, Dr Reddys gets USFDA clearance for its injectables manufacturing facility at Duvvada in Visakhapatnam from all the adverse observations.


    New Delhi: In a major relief to drug major Dr Reddy's Lab, the United States Food and Drug Administration (USFDA) has lifted the warning letter issued to its injectables manufacturing facility at Duvvada in Visakhapatnam. The company recently said it has received the inspection closure report for the facility from the US health regulator.


    Thirty nine months ago it was issued a warning letter along with two of the company's active ingredient (API) plants in November 2015.


    Drug major Dr Reddy's Laboratories Saturday said it has received the inspection closure report for its Duvvada facility in Andhra Pradesh from the US health regulator.


    "We have received a written communication from the United States Food and Drug Administration (USFDA) about the issuance of establishment inspection report (EIR) for FTO VII, our formulations manufacturing facility at Duvvada, Visakhapatnam," Dr Reddy's said in a filing to the BSE.


    Read Also: Dr Reddys shares plunge nearly six per cent after 11 observations by USFDA


    This site was included in the warning letter received from USFDA in November 2015. Subsequently, the site was audited by the regulator in March 2017 for which we received EIR in November 2017, wherein the site's status remained unchanged, it added. The site was again audited in October 2018, Dr Reddy's said.


    Read Also: Dr Reddys launches Tadalafil tablets for treating erectile dysfunction


    "Based on our responses and follow-up actions, the USFDA has concluded that this inspection is 'closed' and has determined the inspection classification of this facility as voluntary action initiated," it added.


    Duvvada formulations unit has been a central manufacturing facility for Dr Reddy's, dedicated to the crucial Oncology injectables.


    Duvvada is the second plant to come out of the warning letter after multiple inspections conducted by the US drug regulator. Prior to this, in June 2017 the API facility in Miryalaguda was issued Establishment Inspection Report (EIR), clearing the facility from all the compliance issues.


    Read Also: Dr Reddys faces price-fixing allegations In US for 4 drugs

    Andhra PradeshBSEDr ReddyDr Reddy DuvvadaDr Reddy'sDr Reddy's DuvvadaDr Reddys Duvvada facilityDr Reddys LabDrug major Dr Reddys LaboratoriesDuvvadaDuvvada facilityEIREstablishment Inspection ReportHealthcare healthindian pharma newslatest pharma newspharma news in indiaPhrama newsUnited States Food and Drug AdministrationUS health regulatorUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok